First COVID-19 vaccine receives interim recommendation, hydroxychloroquine ineffective for prophylaxis, and more
The FDA issued an emergency use authorization for the first mRNA vaccine against SARS-CoV-2, and the CDC's Advisory Committee on Immunization Practices made an interim recommendation for its use in those ages 16 years and older. Other research looked at postexposure prophylaxis, household SARS-CoV-2 transmission, and persistent COVID-19 symptoms.
Still time to register for COVID-19 Vaccine Forum II—Promoting COVID-19 Vaccination: What Physicians Need to Know
The virtual live event hosted by ACP and Annals of Internal Medicine on Wednesday, Dec. 16, will provide unique insight and practical information from a panel of experts on promoting COVID-19 vaccination confidence and uptake.
A 48-year-old woman who works the night shift presents with a one-year history of gaining 25 pounds, as well as fatigue, easy bruising, and difficulty remembering things. Medical history is significant for hypertension, type 2 diabetes, and menopausal hot flushes. After medication review and physical exam, what is the most appropriate next step in evaluation?
While colorectal carcinoid rates are increasing more quickly than colorectal adenocarcinoma rates in younger patients, adenocarcinomas are steadily increasing in almost all early-onset subgroups, including those in their 40s, a U.S. study found.
High-dose flu vaccine may not be more effective than standard dose in patients with high-risk cardiovascular disease
An industry-funded randomized trial in the U.S. and Canada found no significant difference between a high-dose group versus a standard-dose group in the time to first occurrence of all-cause death or cardiopulmonary hospitalization during three flu seasons.
The Executive Committee of the Board of Governors is pleased to announce the Governor-elect Designees representing the Class of 2026.